Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The Company’s lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced Merkel cell carcinoma. In addition, the Company is leveraging its Delta receptor technology to develop novel bi-functional antibody drug conjugates (ADCs), targeting myeloid derived suppressor cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. Its IFx platform technology utilizes a proprietary plasmid DNA (pDNA) or messenger RNA (mRNA). more
Jun '21 | Jun '22 | Jun '23 | Jun '24 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | [{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] | |
Cost of Revenue | 32.00K | - | - | - | [{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] | |
Gross Profit | (32.00K) | - | - | - | [{"date":"2021-06-30","value":-3200000,"profit":false},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] | |
Gross Margin | - | - | - | - | [{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] | |
Operating Expenses | 21.54M | 7.25M | 9.93M | 29.76M | [{"date":"2021-06-30","value":72.37,"profit":true},{"date":"2022-06-30","value":24.37,"profit":true},{"date":"2023-06-30","value":33.37,"profit":true},{"date":"2024-06-30","value":100,"profit":true}] | |
Operating Income | (21.57M) | (7.25M) | (9.93M) | (29.76M) | [{"date":"2021-06-30","value":-2157200000,"profit":false},{"date":"2022-06-30","value":-725498100,"profit":false},{"date":"2023-06-30","value":-993385100,"profit":false},{"date":"2024-06-30","value":-2976472000,"profit":false}] | |
Total Non-Operating Income/Expense | - | (390.81K) | 623.69K | 518.88K | [{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":-62.66,"profit":false},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":83.2,"profit":true}] | |
Pre-Tax Income | (38.30M) | (7.02M) | (9.37M) | (29.32M) | [{"date":"2021-06-30","value":-3829800000,"profit":false},{"date":"2022-06-30","value":-701650900,"profit":false},{"date":"2023-06-30","value":-936751300,"profit":false},{"date":"2024-06-30","value":-2931682600,"profit":false}] | |
Income Taxes | - | - | - | (1.00) | [{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":-100,"profit":false}] | |
Income After Taxes | - | - | - | (29.32M) | [{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":-2931682500,"profit":false}] | |
Income From Continuous Operations | - | (7.02M) | (9.37M) | (29.32M) | [{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":-701650900,"profit":false},{"date":"2023-06-30","value":-936751300,"profit":false},{"date":"2024-06-30","value":-2931682600,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] | |
Net Income | (38.30M) | (7.02M) | (9.37M) | (29.32M) | [{"date":"2021-06-30","value":-3829800000,"profit":false},{"date":"2022-06-30","value":-701650900,"profit":false},{"date":"2023-06-30","value":-936751300,"profit":false},{"date":"2024-06-30","value":-2931682500,"profit":false}] | |
EPS (Diluted) | (3.46K) | (979.26) | (328.34) | - | [{"date":"2021-06-30","value":-346177.6,"profit":false},{"date":"2022-06-30","value":-97926.21,"profit":false},{"date":"2023-06-30","value":-32834.25,"profit":false},{"date":"2024-06-30","value":"-","profit":true}] | |
These ratios help you determine the liquidity of the company. Higher is better.
HURA | |
---|---|
Cash Ratio | 1.34 |
Current Ratio | 1.54 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
HURA | |
---|---|
ROA (LTM) | 0.00% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
HURA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.59 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.41 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
HURA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 119.45 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
TuHURA BionSciences Inc (HURA) share price today is $4.48
Yes, Indians can buy shares of TuHURA BionSciences Inc (HURA) on Vested. To buy TuHURA BionSciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HURA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of TuHURA BionSciences Inc (HURA) via the Vested app. You can start investing in TuHURA BionSciences Inc (HURA) with a minimum investment of $1.
You can invest in shares of TuHURA BionSciences Inc (HURA) via Vested in three simple steps:
The 52-week high price of TuHURA BionSciences Inc (HURA) is $14.6. The 52-week low price of TuHURA BionSciences Inc (HURA) is $2.83.
The price-to-earnings (P/E) ratio of TuHURA BionSciences Inc (HURA) is
The price-to-book (P/B) ratio of TuHURA BionSciences Inc (HURA) is 119.45
The dividend yield of TuHURA BionSciences Inc (HURA) is 0.00%
The market capitalization of TuHURA BionSciences Inc (HURA) is $141.65M
The stock symbol (or ticker) of TuHURA BionSciences Inc is HURA